PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases
PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases
复制标题
DOI：
10.1097/dad.0000000000001164
复制
发表时间：
2018-09-01
影响因子：
1.1
通讯作者：
Toll, Agusti
中科院分区：
文献类型：
--
作者：
Garcia-Diez, Irene;Hernandez-Ruiz, Eugenia;Toll, Agusti
肿瘤细胞表达的程序性细胞死亡配体1（PD-L1）在抑制肿瘤中T细胞介导的免疫应答中起重要作用。肿瘤细胞的PD-L1表达与多种癌症的不良预后有关。然而，PD-L1在皮肤鳞状细胞癌（cSCC）中的表达几乎没有研究，其作为预后生物标志物的作用仍然存在争议。评估了PD-L1表达与一系列cSCC转移风险的相关性。对99例原发性肿瘤和24例淋巴转移瘤的全切除切片进行PD-L1和CD 8免疫染色半定量评价。根据淋巴转移扩散[转移性鳞状细胞癌（MSCC）]（n = 48）或无进展[非转移性鳞状细胞癌（NMSCC）]（n = 51）对原发性cSCC进行分组。PD-L1阳性表达（cutoff>= 1%）在26%的NMSCC和50%的MSCC中发现（P = 0.02）。多变量分析证实PD-L1与转移风险增加相关（P < 0.05），沿着以下特征：复发、分化差和神经周围浸润。90%的PD-L1阳性肿瘤转移灶也呈PD-L1阳性，与原发性肿瘤相比，显示出PD-L1表达更高的趋势（P = 0.058）。转移性和非转移性原发性肿瘤的瘤周炎性浸润或CD 8表达无显著差异。我们的研究结果表明，PD-L1可能在转移扩散中发挥相关作用，并可能成为cSCC的候选预后生物标志物。
Programmed cell death ligand 1 (PD-L1) expression by tumor cells plays an important role in the inhibition of T cell-mediated immune response in cancer. PD-L1 expression by tumor cells has been linked to poor prognosis in a wide variety of cancers. However, PD-L1 expression in cutaneous squamous cell carcinoma (cSCC) has been scarcely studied, and its role as a prognosis biomarker remains controversial. The association of PD-L1 expression and the metastatic risk in a series of cSCC was assessed. PD-L1 and CD8 immunostainings of full excision sections of 99 primary tumors and 24 lymphatic metastases were semiquantitatively evaluated. Primary cSCCs were grouped according to the development of lymphatic metastatic spread [metastasizing squamous cell carcinoma (MSCC)] (n = 48) or the absence of progression [nonmetastasizing squamous cell carcinoma (NMSCC)] (n = 51). PD-L1-positive expression (cut off >= 1%) was found in 26% NMSCCs and in 50% MSCCs (P = 0.02). PD-L1 association with an increased metastatic risk was confirmed in the multivariate analysis (P < 0.05), along with the following features: recurrence, poor differentiation, and perineural invasion. Ninety percent of the metastases of PD-L1-positive tumors were also positive for PD-L1, displaying a trend toward a higher PD-L1 expression when compared with their primary tumors (P = 0.058). No significant differences in the peritumoral inflammatory infiltrate or in the expression of CD8 were found between metastasizing and nonmetastasizing primary tumors. Our results suggest that PD-L1 may play a relevant role in metastatic spread and may be a candidate prognostic biomarker in cSCC.